|
|
||||||||
| Neurology supplements are not peer-reviewed. Information contained in Neurology supplements represent the opinions of the authors and are not endorsed by nor do they reflect the views of the American Academy of Neurology, Editor-in-Chief, or Associate Editors of Neurology. |
From the Department of Neurology, School of Medicine, Emory University, Atlanta, GA 30322.
Address correspondence and reprint requests to Dr. Thomas R. Henry, Department of Neurology, Emory University, Woodruff Memorial Research Building, Suite 6000, 1639 Pierce Drive, Atlanta, GA 30322.
Article abstract Experiments in acute and chronic animal models of epilepsy provide mechanistic insight into the acute abortive, acute prophylactic, and chronic progressive prophylactic, anti-seizure effects of vagus nerve stimulation (VNS) observed in human epilepsies, and demonstrate antiepileptogenic effects of VNS in the kindling model. Anatomic-physiologic studies, experimental epilepsy studies, and human imaging, EEG, and CSF studies suggest that multiple mechanisms underlie the antiseizure effects of VNS and that alterations of vagal parasympathetic efferent activities do not underlie these antiseizure effects. Putative antiseizure mechanisms are mediated by altered vagal afferent activities, and probably include altered activities in the reticular activating system, the central autonomic network, the limbic system, and the diffuse noradrenergic projection system. Anatomic-physiologic studies fully account for the common and rare adverse effects of VNS. Current understandings of antiepileptic drug (AED) and VNS therapeutic mechanisms strongly support the "common sense" interpretation of the clinical studies: i.e., adjunctive VNS can add antiseizure effect to any AED regimen, with no interactive toxicity and no effect on drug distribution and elimination.
This article has been cited by other articles:
![]() |
B. Bauer, A. M. S. Hartz, A. Pekcec, K. Toellner, D. S. Miller, and H. Potschka Seizure-Induced Up-Regulation of P-Glycoprotein at the Blood-Brain Barrier through Glutamate and Cyclooxygenase-2 Signaling Mol. Pharmacol., May 1, 2008; 73(5): 1444 - 1453. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. W. Hatton, J. T. McLarney, T. Pittman, and B. G. Fahy Vagal Nerve Stimulation: Overview and Implications for Anesthesiologists Anesth. Analg., November 1, 2006; 103(5): 1241 - 1249. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-I. Ito and A. D. Craig Vagal-Evoked Activity in the Parafascicular Nucleus of the Primate Thalamus J Neurophysiol, October 1, 2005; 94(4): 2976 - 2982. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Heck, S. L. Helmers, and C. M. DeGiorgio Vagus nerve stimulation therapy, epilepsy, and device parameters: Scientific basis and recommendations for use Neurology, September 24, 2002; 59(90064): S31 - 37. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |